< Previous page
All
Airlines/Aviation
Auto
Maritime/Shipbuilding
Transportation
Computer Hardware
Computer Networks
Computer Software
Computer/Electronics
Electronic Commerce
Electronic Components
High Tech Security
Internet Technology
Peripherals
Semiconductors
Electronics Gaming
Consumer Electronics
Mobile Entertainment
Multimedia/Online/Internet
Telecommunications
Household/Consumer/Cosmetics
Retail
Supermarkets
Toys
Alternative Energies
Chemical
Mining/Metals
Oil/Energy
Environmental Products & Services
Green Technology
Art
Cosmetics & Personal Care
Entertainment
Fashion
Film & Motion Picture
Jewelry
Banking/Financial Service
Insurance
Workforce Management/Human Resources
Education
Higher Education
Biotechnology
Health Care/Hospital
Infectious Disease Control
Medical Equipment
Medical/Pharmaceuticals
Agriculture
Machinery
Paper/Forest Products/Containers
Textiles
Domestic policy
Legal issues
Sports
Hotels and Resorts
Leisure/Travel/Hotels
Travel
Restaurants
Beer, Wine & Spirits
Beverages
Non-Alcoholic Beverages
Food/Beverages
Advertising
Books
Music
Publishing/Information Service
Television
Trade show news
Real Estate
Construction/Building
Furniture & Furnishings
|
Title only
|
Print
Next page >
88IV - PR Newswire Asia's news - Health Care/Hospital
5
Smartee Mandibular Advancement Repositioning Seminar Draws Active Clinical Dialogue in Tokyo
TOKYO , May 30, 2026 /PRNewswire/ -- Smartee Denti-Technology , a global provider of clear aligner solutions, recently held a two-day Certified Seminar on Mandibular Advancement Repositioning Technology ...
2026-06-01T
Computer/Electronics
Health Care/Hospital
Trade show news
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
BEIJING , June 1, 2026 /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical ...
2026-06-01T
Health Care/Hospital
Medical Equipment
Medical/Pharmaceuticals
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
SHANGHAI , June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology ...
2026-06-01T
Health Care/Hospital
Medical/Pharmaceuticals
Trade show news
Driving Innovation, Empowering Partners: ACROBiosystems Showcases Comprehensive CGT Solutions Anchored by GMP Capabilities at Bio Korea 2026
SEOUL, South Korea , June 1, 2026 /PRNewswire/ -- ACROBiosystems, a biotechnology company positioning itself as a cornerstone of the global biopharmaceutical and healthcare industries, participated in ...
2026-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China , June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for ...
2026-06-01T
Health Care/Hospital
Medical/Pharmaceuticals
Trade show news
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications ...
2026-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO , June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T ...
2026-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective ...
2026-06-01T
Health Care/Hospital
Medical/Pharmaceuticals
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI , June 1, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis ...
2026-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema
HANGZHOU, China, SHANGHAI and BOSTON , June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on ...
2026-06-01T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
< Previous page
Next page >
Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.